Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Distribution for cost

From: A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer

 

BSC ARM

Medical and other pharmaceutical cost in progression free stage

Progression stage

Sorafenib arm

Sorafenib cost

Medical and other pharmaceutical cost in progression free stage

Cost in the progression stage 1 stand 2 ndmonth

3 ndMonth and further on

Cost (euro) 2012

 

278

770

 

2880

357

1499 1

770

Type of distribution

 

Gamma

Gamma

 

Uniform

Gamma

Gamma

Gamma

Distribution parameters α, β

 

(1336, 4.8)

(3696, 4.8)

 

(2880,2900)

(1714, 4.8)

(7196, 4.8)

(3696, 4.8)

  1. 1Provides that patients will continue sorafenib for one month after progression until diagnosis is confirmed.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us